For decades, the dominant strategy in Alzheimer's disease (AD) therapeutics focused almost exclusively on the amyloid cascade hypothesis. The core intuition was simple: clear the amyloid-beta (Aβ) plaques, and you halt the disease. However, repeated clinical trial failures and modest symptomatic benefits have forced a profound paradigm shift. As argued by Allan I. Levey et al. in their evaluation of noradrenergic neuroprotection [A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment], targeting a single protein aggregate fails to address the broader, interconnected web of neurodegeneration.
Instead of treating AD as a monolithic proteinopathy, modern research frames it as a multifactorial systemic failure of the brain. A data-driven multimodal analysis by Yasser Iturria‐Medina et al. [Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis] demonstrated that vascular dysregulation is likely the earliest pathological event in late-onset AD, often preceding significant protein accumulation. To build effective treatments, the field is pivoting toward alternative pathways: neuroinflammation, metabolic crisis, ferroptosis, and network-level circuit degradation.
Resolving the Neuroinflammatory Vicious Cycle
In a healthy brain, microglia act as diligent caretakers, clearing cellular debris and maintaining synaptic health. In the presence of chronic AD pathology, however, these cells undergo a dangerous phenotypic shift, becoming chronically activated and neurotoxic.
To understand why this transition happens, You Jung Kang et al. investigated the microglial microenvironment [Neurotoxic Microglial Activation via IFNγ‐Induced Nrf2 Reduction Exacerbating Alzheimer's Disease]. The authors found that elevated interferon-gamma (IFNγ) in the AD brain downregulates Nrf2, a master regulator of the cellular antioxidant response. Deprived of Nrf2, microglia suffer from severe oxidative stress and pivot into a pro-inflammatory state that actively destroys surrounding neurons.
[IFNγ Elevation] ──> [Nrf2 Reduction] ──> [Microglial Oxidative Stress] ──> [Neurotoxic Inflammation]
Breaking this inflammatory loop requires multi-target interventions that protect synapses while dampening hyper-inflammation. For example, Shu Shu et al. demonstrated that inhibiting the pro-inflammatory protein S100A9 simultaneously reduces new plaque formation and rescues existing synaptic integrity [Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice]. Furthermore, as single-author Rui-Dan Hu showed, targeting downstream inflammatory complexes like the NLRP3 inflammasome can alleviate cognitive decline by restoring cholinergic function [Ethanol extract of Evodia lepta Merr. ameliorates cognitive impairment through inhibiting NLRP3 inflammasome in scopolamine-treated mice]. This highlights why the classic cholinergic hypothesis was incomplete: acetylcholine deficiency is not an isolated defect, but a casualty of upstream inflammatory damage.
Countering Metabolic Failure: Mitophagy and Ferroptosis
Neurons are exceptionally energy-hungry cells. When their internal power plants—mitochondria—fail, or when lipid membranes degrade, the cell triggers self-destruction pathways. Two critical mechanisms dominate this metabolic crisis: the failure of mitochondrial recycling (mitophagy) and iron-dependent cell death (ferroptosis).
When mitophagy stalls, damaged mitochondria accumulate, leaking reactive oxygen species (ROS) and starving the neuron of ATP. To address this, Chenglong Xie et al. deployed a machine-learning pipeline to discover small-molecule mitophagy inducers, such as Kaempferol and Rhapontigenin [Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow]. By jumpstarting the clearance of defective mitochondria, these compounds restore cellular energy balance and reverse memory loss without directly targeting amyloid plaques. Similarly, Massimiliano Runfola et al. developed pleiotropic thyroid hormone derivatives that trigger metabolic reprogramming and autophagy, providing broad neuroprotection with minimal systemic toxicity [Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease].
Concurrently, iron accumulation in the AD brain drives ferroptosis, where lipid peroxidation destroys the structural integrity of neuronal membranes. As synthesized by Bingyuan Zhou et al., iron overload and lipid peroxidation form a destructive feedback loop with classic Aβ and tau pathologies [Insights into targeted ferroptosis in mechanisms, biology, and role of Alzheimer's disease: an update]. Intercepting this metabolic collapse requires regulating lipid pathways; Kai Gong et al. demonstrated that modulating the AMPK/Sp1/ACSL4 axis can directly inhibit neuronal ferroptosis, protecting the lipid landscape of the vulnerable hippocampus [Danggui Shaoyao San ameliorates Alzheimer’s disease by regulating lipid metabolism and inhibiting neuronal ferroptosis through the AMPK/Sp1/ACSL4 signaling pathway].
Systemic and Network-Level Modulation
Because Alzheimer's disease ultimately degrades distributed neural networks rather than isolated brain regions, effective therapies must scale their mechanism of action to the network level.
This network-centric intuition explains why localized interventions often fall short. In a systematic review of repetitive transcranial magnetic stimulation (rTMS), Ke Dong et al. discovered that stimulating multiple nodes within the brain's cognitive networks simultaneously produces far greater cognitive improvements than targeting a single region [Comparative efficacy of rTMS on different targets in Alzheimer’s disease: a systematic review and meta-analysis]. By modulating interconnected circuits, multi-target stimulation helps restore the functional connectivity that single-target approaches leave unaddressed.
[Single-Target rTMS] ──> Isolated node modulation (Limited circuit recovery)
[Multi-Target rTMS] ──> Distributed network modulation (Significant cognitive rescue)
This principle applies equally to pharmacology. Single-author Le Xie demonstrated that combining standard neurotransmitter-focused therapies (Donepezil) with vascular-improving agents (Ginkgo biloba extract) yields superior outcomes in patients experiencing cognitive decline [Efficacy and safety of ginkgo biloba extract combined with donepezil hydrochloride in the treatment of Chinese patients with vascular dementia: A systematic review meta-analysis]. The combination works because it simultaneously addresses two distinct physiological failures: neurotransmitter depletion and reduced cerebral blood flow.
To map and exploit these complex, multi-pathway interactions, researchers are moving away from trial-and-error drug discovery. Joseph D. Romano et al. constructed the Alzheimer's Knowledge Base (AlzKB), a semantically unified knowledge graph designed to integrate diverse biomedical data [The Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research]. By using machine learning to analyze these complex biological networks, researchers can systematically discover pleiotropic compounds capable of hitting multiple alternative pathways at once—offering a more robust strategy against the multifactorial nature of neurodegeneration.
Key Foundational Work
Protein Sequence Alignment Algorithm Based on Hybrid Profile Information (2010) — contributed 2 concept elements to this direction.